Research area

Regenerative research

Compounds studied in regenerative research research: what each trial measured, and links to the sources.

GHK-Cu

Clinical evidence

Genuinely strong, repeated clinical trial evidence for wound healing and scar reduction in humans: one of the best-evidenced compounds in this catalog, with completed human trials behind it.

The best-evidenced compound in this category. A current Phase 2 randomized, double-blind, vehicle-controlled trial (ClinicalTrials.gov) is testing topical GHK-Cu gel on standardized skin wounds in healthy adults. Completed human studies: a 2023 Phase 2 trial in 40 post-surgical patients found 0.5% GHK-Cu gel reduced scar volume by 35% at 3 months vs. silicone (statistically significant, p=0.002); a 2021 RCT in 72 diabetic ulcer patients found 85% wound closure at 12 weeks with GHK-Cu dressings vs. 55% control; a human comparison trial found topical GHK-Cu increased collagen in 70% of volunteers, outperforming both vitamin C and retinoic acid comparators. Chronic venous ulcer trials also show accelerated healing and granulation tissue formation vs. placebo.

Sources

BPC-157

Community evidence

Has real human trial data for an inflammatory gut condition. For the injury and tendon healing it is typically associated with, the evidence to date is preclinical: 100+ animal studies plus one small observational report.

Important distinction: BPC-157 does have real human trial data. A Phase 2 trial for ulcerative colitis (Croatia) found statistically significant dose-dependent improvement in endoscopic/clinical scores, and Croatian trials in the early 2000s found it safe and effective for inflammatory bowel disease. The injury, tendon and muscle healing use that represents the majority of how people actually use this compound rests on preclinical evidence: 100+ animal studies plus one small, low-quality observational study (7 of 12 people with chronic knee pain reported relief 6+ months after one injection). Human safety data covers the gut-condition trials; the injury-recovery use case remains preclinical.

Sources

TB-500

Community evidence

The human trial data commonly cited for this compound comes from full-length Thymosin Beta-4, a related but larger molecule applied topically. Evidence for TB-500 itself, the 17-amino-acid fragment sold as a peptide, is preclinical.

Critical distinction: as of this research, evidence for TB-500 (the 17-amino-acid fragment sold as a peptide) is preclinical across every tissue-repair indication. The human clinical trial data that does exist (two Phase 2 trials in venous stasis ulcers and pressure ulcers, showing healing accelerated by nearly a month, safe and well-tolerated) used full-length Thymosin Beta-4, a related but larger molecule, applied topically. Preclinical (animal and cell) research on Tβ4 broadly supports accelerated wound healing mechanisms; whether TB-500 specifically, as an injected peptide, reproduces that effect is still an open question.

Sources

KPV (Alpha-MSH Fragment)

Community evidence

A well-understood anti-inflammatory mechanism, with an evidence base that is entirely preclinical: animal models and laboratory research.

A tripeptide derived from alpha-MSH with a well-studied anti-inflammatory mechanism (blocks NF-kB signaling, reducing nuclear translocation by up to 80% in lab models). Anti-inflammatory effects are documented in animal models of colitis and peritonitis. The evidence base is preclinical: animal models and laboratory research.

Sources

This is a summary of published and preclinical research, not medical advice. Every entry describes what a study found, not what you should do. These compounds are supplied for laboratory research only.

All research areas